{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T09:14:03Z","timestamp":1721812443880},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,9]]},"DOI":"10.7759\/cureus.22070","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T03:26:56Z","timestamp":1644463616000},"source":"Crossref","is-referenced-by-count":4,"title":["Rare Adverse Events Related to Nivolumab, an Immune Checkpoint Inhibitor: A Case Series"],"prefix":"10.7759","author":[{"given":"Nagapratap","family":"Ganta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Alnabwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawn","family":"Keating","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vraj","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veera Jayasree Latha","family":"Bommu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rand","family":"Dawoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pramil","family":"Cheriyath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4158\/ep161491.cr","article-title":"Nivolumab-induced isolated adrenal insufficiency: a case report","volume":"3","author":"Neril R","year":"2017","unstructured":"Neril R, Lorton J, Zonszein J. Nivolumab-induced isolated adrenal insufficiency: a case report. AACE Clin Case Rep. 2017, 3:210-2. 10.4158\/ep161491.cr","journal-title":"AACE Clin Case Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159\/000507652","article-title":"Primary adrenal insufficiency during immune checkpoint inhibitor treatment: case reports and review of the literature","volume":"13","author":"Salinas C","year":"2020","unstructured":"Salinas C, Renner A, Rojas C, Samtani S, Burotto M. Primary adrenal insufficiency during immune checkpoint inhibitor treatment: case reports and review of the literature. Case Rep Oncol. 2020, 13:621-6. 10.1159\/000507652","journal-title":"Case Rep Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.7625","article-title":"Nivolumab induced adrenal insufficiency: rare side-effect of a new anti-cancer therapy - immune-checkpoint inhibitors","volume":"12","author":"Rai M","year":"2020","unstructured":"Rai M, Go M. Nivolumab induced adrenal insufficiency: rare side-effect of a new anti-cancer therapy - immune-checkpoint inhibitors. Cureus. 2020, 12:e7625. 10.7759\/cureus.7625","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.anl.2019.05.009","article-title":"Adrenal insufficiency following nivolumab therapy in patients with recurrent or metastatic head and neck cancer","volume":"47","author":"Kagoshima H","year":"2020","unstructured":"Kagoshima H, Hori R, Kojima T, Okanoue Y, Fujimura S, Taguchi A, Shoji K. Adrenal insufficiency following nivolumab therapy in patients with recurrent or metastatic head and neck cancer. Auris Nasus Larynx. 2020, 47:309-13. 10.1016\/j.anl.2019.05.009","journal-title":"Auris Nasus Larynx"},{"key":"ref5","article-title":"Adrenal Insufficiency [Updated 2017 Oct 14]","author":"Nicolaides NC","year":"2000","unstructured":"Nicolaides NC, Chrousos GP, Charmandari E. Adrenal Insufficiency [Updated 2017 Oct 14]. Endotext [Internet]. Feingold KR, Anawalt B, Boyce A, et al. (ed): MDText.com, Inc., South Dartmouth; 2000."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice guideline summary","volume":"14","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Thompson JA. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice guideline summary. J Oncol Pract. 2018, 14:247-9. 10.1200\/JOP.18.00005","journal-title":"J Oncol Pract"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang DY","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al.. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:1721-8. 10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","author":"Yang JC","year":"2007","unstructured":"Yang JC, Hughes M, Kammula U, et al.. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007, 30:825-30. 10.1097\/CJI.0b013e318156e47e","journal-title":"J Immunother"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-012-4379-7","article-title":"Cross-reactivity of anti-programmed death ligand 2 polyclonal antibody in mouse tissues","volume":"55","author":"Zhao Y","year":"2012","unstructured":"Zhao Y, Bian G, Yu C, et al.. Cross-reactivity of anti-programmed death ligand 2 polyclonal antibody in mouse tissues. Sci China Life Sci. 2012, 55:940-7. 10.1007\/s11427-012-4379-7","journal-title":"Sci China Life Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.764138","article-title":"Unravelling checkpoint inhibitor associated autoimmune diabetes: from bench to bedside","volume":"12","author":"Wu L","year":"2021","unstructured":"Wu L, Tsang VH, Sasson SC, et al.. Unravelling checkpoint inhibitor associated autoimmune diabetes: from bench to bedside. Front Endocrinol (Lausanne). 2021, 12:764138. 10.3389\/fendo.2021.764138","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00474","article-title":"Fulminant type 1 diabetes mellitus caused by drug reaction with eosinophilia and systemic symptoms (DRESS): a case report and review of the literature","volume":"10","author":"Zhu B","year":"2019","unstructured":"Zhu B, Wu J, Chen G, Yang Y, Yi C. Fulminant type 1 diabetes mellitus caused by drug reaction with eosinophilia and systemic symptoms (DRESS): a case report and review of the literature. Front Endocrinol (Lausanne). 2019, 10:474. 10.3389\/fendo.2019.00474","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0459","article-title":"Reporting of immune checkpoint inhibitor therapy-associated diabetes, 2015-2019","volume":"43","author":"Liu J","year":"2020","unstructured":"Liu J, Zhou H, Zhang Y, Fang W, Yang Y, Huang Y, Zhang L. Reporting of immune checkpoint inhibitor therapy-associated diabetes, 2015-2019. Diabetes Care. 2020, 43:e79-80. 10.2337\/dc20-0459","journal-title":"Diabetes Care"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18679","article-title":"New-onset type 1 diabetes mellitus after treatment with nivolumab for melanoma","volume":"13","author":"Baroud S","year":"2021","unstructured":"Baroud S, Mirza L. New-onset type 1 diabetes mellitus after treatment with nivolumab for melanoma. Cureus. 2021, 13:e18679. 10.7759\/cureus.18679","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2349","article-title":"Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy","volume":"38","author":"Hughes J","year":"2015","unstructured":"Hughes J, Vudattu N, Sznol M, Gettinger S, Kluger H, Lupsa B, Herold KC. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care. 2015, 38:e55-7. 10.2337\/dc14-2349","journal-title":"Diabetes Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/84562-rare-adverse-events-related-to-nivolumab-an-immune-checkpoint-inhibitor-a-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:37:21Z","timestamp":1707507441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/84562-rare-adverse-events-related-to-nivolumab-an-immune-checkpoint-inhibitor-a-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.22070","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,9]]}}}